<DOC>
	<DOCNO>NCT00442637</DOCNO>
	<brief_summary>The optimal duration systemic treatment patient advance colorectal cancer unknown . In study effect bevacizumab low-dose continuous chemotherapy capecitabine investigate patient respond 6 course oxaliplatin , capecitabine bevacizumab ( `` induction treatment '' , standard dos ) . This treatment continue progression severe toxicity . This regimen compare effect observation without treatment induction treatment . In case disease progression , induction treatment reintroduce .</brief_summary>
	<brief_title>Maintenance Treatment Versus Observation After Induction Advanced Colorectal Carcinoma</brief_title>
	<detailed_description>Standard 1st-line treatment patient advance colorectal cancer currently consist chemotherapy plus bevacizumab . With approach median overall survival approximately 20 month , progression-free survival first-line approximately 9-11 month . The optimal duration treatment unknown . Current data suggest efficacy bevacizumab dependent concomitant use chemotherapy . However , oxaliplatin almost invariably give rise neuropathy 6-8 cycle . Prolonged use capecitabine associate e.g . hand-foot syndrome . Lastly , prolong use agent associate considerable cost . Evidence , mainly preclinical , suggest continuous dose metronomic chemotherapy may efficacious interval-chemotherapy give MTD . In study concept metronomic chemotherapy explore administer continuous daily instead usual 2 weeks-on/1 week-off oral dose regimen low-dose capecitabine plus bevacizumab maintenance therapy induction combination chemotherapy give MTD plus bevacizumab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Before start induction therapy : Histological proof colorectal cancer ( case single metastasis , histological cytological proof lesion obtain ) ; Distant metastasis ( patient local recurrence eligible ) ; Unidimensionally measurable disease ( &gt; 1 cm spiral CT scan &gt; 2 cm chest Xray ; liver ultrasound allow ) . Serum CEA may use parameter disease evaluation ; In case previous radiotherapy , least one measurable lesion locate outside irradiated field . Ongoing plan first line treatment 6 cycle Xeloda , Eloxatin , Avastin . Exclusion criterion Prior adjuvant treatment stage II/III colorectal cancer end within 6 month start induction treatment Any prior adjuvant treatment resection distant metastases Previous systemic treatment advance disease At randomisation : Inclusion criterion : WHO performance status 01 ( Karnofsky PS &gt; 70 % ) ; Disease evaluation proven SD , PR CR accord RECIST 6 cycle MTD chemotherapy perform week 34 6th cycle induction therapy , randomisation perform week 35 6th cycle ( see time table ) ; Laboratory value obtain ≤ 2 week prior randomisation : adequate bone marrow function ( Hb &gt; 6.0 mmol/L , absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , &gt; 30 ml/min ) , liver function ( serum bilirubin ≤ 2 x ULN , serum transaminase ≤ 3 x ULN without presence liver metastases ≤ 5x ULN presence liver metastasis ) ; Life expectancy &gt; 12 week ; Age &gt; = 18 yr ; Negative pregnancy test woman childbearing potential ; Expected adequacy followup ; Institutional Review Board approval ; Written inform consent Exclusion criterion History clinical signs/symptoms CNS metastasis ; History second malignancy ≤ 5 year exception adequately treat carcinoma cervix basal/squamous cell carcinoma skin ; Previous intolerance XelodaR , EloxatinR , and/or AvastinR drug permanently discontinue ; patient previous dose reduction delay eligible ; patient grade 2 neurotoxicity 6th cycle eligible , retreatment EloxatinR PFS1 depend grade neurotoxicity moment ; Known dihydropyrimidine dehydrogenase ( DPD ) deficiency ; ( Planned ) radical resection metastatic disease ; Uncontrolled hypertension , i.e . consistently &gt; 150/100 mmHg ; Use 3 antihypertensive drug ; Significant cardiovascular disease &lt; 1 yr randomisation ( symptomatic congestive heart failure , myocardial ischemia infarction , unstable angina pectoris , serious uncontrolled cardiac arrhythmia , arterial thrombosis , cerebrovascular event , pulmonary embolism ) ; Any significant cardiovascular event previous fluoropyrimidine therapy ; Chronic active infection ; Any concurrent severe uncontrolled disease prevent safe administration study drug ; Any impairment gastrointestinal function disease may significantly impair absorption oral drug ( i.e . uncontrolled nausea , vomit , diarrhoea ( define &gt; CTC grade 2 ) , malabsorption syndrome , bowel obstruction , inability swallow tablet ) ; Concomitant treatment : concomitant ( within 4 week randomisation ) administration experimental drug investigation ; concurrent treatment anticancer therapy ; fulldose anticoagulation ( allow start induction therapy ) ; Continuous use immunosuppressive agent ( except use corticosteroid antiemetic prophylaxis/treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CAIRO3</keyword>
	<keyword>DCCG</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>induction</keyword>
	<keyword>metronomic chemotherapy</keyword>
	<keyword>observation</keyword>
	<keyword>capecitabine</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>